Rezolute Inc
Change company Symbol lookup
Select an option...
RZLT Rezolute Inc
BAC Bank of America Corp
SDA SunCar Technology Group Inc
RAIN Rain Oncology Inc
EOI Eaton Vance Enhanced Equity Income Fund
OLNCF Omni Lite Industries Canada Inc
RGNX Regenxbio Inc
OGSYS Otis Gallery LLC
RDN Radian Group Inc
SLNO Soleno Therapeutics Inc
Go

Health Care : Biotechnology | Small Cap Value

Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Price: Delayed
$1.99

Day's Change: 0.02 (1.02%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.05

Day's Low: 1.99

Volume (Light) Today's volume of 716 shares is on pace to be much lighter than RZLT's 10-day average volume of 13,011 shares.: 716

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.